Long-term safety study of a blood protein for Alpha-1
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study checks how safe a prescribed blood protein medicine (alpha-1 proteinase inhibitor) is over the long term in people with Alpha-1 antitrypsin deficiency. You may join if you already finished an earlier study or if your lung function has been declining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have finished the earlier Alpha-1 study (including the late study visits) OR your lung function declined enough during that study
- You can sign an informed consent form and understand the study
- You must be able to complete chest CT scans (not too claustrophobic and physically able to fit in the scanner)
- You cannot have severe major ongoing illnesses like severe heart failure or liver cirrhosis
- You must not have current cancer expected to limit survival to under 1 year
- You must not have new metal in your body that could interfere with CT images
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This trial tests a new treatment called CTX460, which is a type of gene therapy that may correct the genetic defect causing alpha-1 antitrypsin deficiency (AATD) and help slow or improve emphysema. It's designed for adults with severe AATD and emphysema who have not had a liver or lung transplant.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This study tests a weekly injection of a protein replacement therapy for adults with emphysema due to alpha-1 antitrypsin deficiency. The goal is to see if this treatment can slow down the loss of lung density over three years.
This study tests a one-time gene therapy called BEAM-302 that aims to fix the faulty gene causing alpha-1 antitrypsin deficiency (AATD), a condition that damages the lungs and liver. The goal is to improve AAT levels and slow or stop disease progression.
Hear when a new Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.